AbbVie (NYSE:ABBV) Stock Rating Upgraded by Leerink Partnrs

Leerink Partnrs upgraded shares of AbbVie (NYSE:ABBV) from a hold rating to a strong-buy rating in a research report report published on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for AbbVie’s FY2026 earnings at $13.69 EPS, FY2027 earnings at $15.36 EPS and FY2028 earnings at $16.79 EPS.

A number of other brokerages have also issued reports on ABBV. William Blair upgraded shares of AbbVie to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price on the stock in a research report on Friday. BMO Capital Markets cut their target price on AbbVie from $228.00 to $208.00 and set an “outperform” rating for the company in a research note on Tuesday, November 12th. Truist Financial increased their price target on shares of AbbVie from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, UBS Group lifted their price target on shares of AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $203.50.

AbbVie Price Performance

ABBV stock opened at $177.06 on Friday. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The company has a market capitalization of $312.89 billion, a P/E ratio of 61.48, a PEG ratio of 2.16 and a beta of 0.63. The business has a 50 day simple moving average of $189.09 and a 200-day simple moving average of $181.44. AbbVie has a twelve month low of $137.65 and a twelve month high of $207.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. The firm had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. AbbVie’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.95 EPS. As a group, equities analysts anticipate that AbbVie will post 10.95 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $1.64 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.55. The ex-dividend date is Wednesday, January 15th. This represents a $6.56 annualized dividend and a yield of 3.70%. AbbVie’s payout ratio is 227.78%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Fairway Wealth LLC acquired a new position in AbbVie during the second quarter worth approximately $26,000. Ridgewood Investments LLC acquired a new position in AbbVie in the second quarter valued at $27,000. Groupama Asset Managment grew its position in AbbVie by 40.3% during the third quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock valued at $27,000 after acquiring an additional 38,974 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth about $28,000. Finally, Quest Partners LLC raised its holdings in AbbVie by 4,140.0% in the second quarter. Quest Partners LLC now owns 212 shares of the company’s stock valued at $36,000 after buying an additional 207 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.